Medexus Pharmaceuticals (MDP) Competitors C$2.43 +0.05 (+2.10%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades MDP vs. EPI, ICC, RIV, LEAF, CRDL, RX, HLS, TGOD, NINE, and WMDShould you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), and WeedMD (WMD). These companies are all part of the "drug manufacturers - specialty & generic" industry. Medexus Pharmaceuticals vs. ESSA Pharma ICC Labs RIV Capital Leaf Mobile Cardiol Therapeutics BioSyent HLS Therapeutics Green Organic Dutchman Delta 9 Cannabis WeedMD Medexus Pharmaceuticals (TSE:MDP) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Does the media refer more to MDP or EPI? In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than ESSA Pharma. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for ESSA Pharma. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score. Company Overall Sentiment Medexus Pharmaceuticals Neutral ESSA Pharma Neutral Do institutionals & insiders hold more shares of MDP or EPI? 8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend MDP or EPI? Medexus Pharmaceuticals currently has a consensus target price of C$5.88, suggesting a potential upside of 141.77%. Given Medexus Pharmaceuticals' higher possible upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50ESSA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has better earnings and valuation, MDP or EPI? Medexus Pharmaceuticals has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedexus PharmaceuticalsC$108.78M0.55C$1.09MC$0.0548.60ESSA PharmaN/AN/AN/A-C$0.99-8.27 Is MDP or EPI more profitable? Medexus Pharmaceuticals has a net margin of 1.00% compared to ESSA Pharma's net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 3.95% beat ESSA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medexus Pharmaceuticals1.00% 3.95% 4.89% ESSA Pharma N/A N/A N/A Does the MarketBeat Community believe in MDP or EPI? ESSA Pharma received 59 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Medexus Pharmaceuticals an outperform vote while only 72.41% of users gave ESSA Pharma an outperform vote. CompanyUnderperformOutperformMedexus PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesESSA PharmaOutperform Votes6372.41% Underperform Votes2427.59% SummaryMedexus Pharmaceuticals beats ESSA Pharma on 13 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDP vs. The Competition Export to ExcelMetricMedexus PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$59.61MC$1.22BC$5.39BC$5.94BDividend YieldN/A3.13%5.13%5.37%P/E Ratio48.60110.69114.3725.87Price / Sales0.553,426.271,489.561,515.70Price / CashN/A10.1939.6781.06Price / Book1.833.174.663.11Net IncomeC$1.09MC$155.16MC$119.06MC$292.76M7 Day Performance-5.08%-0.02%0.80%-1.67%1 Month Performance-5.45%-0.71%5.65%2.31%1 Year Performance19.70%100.92%36.75%45.72% Medexus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDPMedexus Pharmaceuticals2.3022 of 5 starsC$2.43+2.1%C$5.88+141.8%+20.3%C$59.61MC$108.78M48.6098Upcoming EarningsNews CoverageEPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725ICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/AGap UpRIVRIV CapitalN/AN/AN/AN/AC$213.65MC$11.33M-1.6312LEAFLeaf MobileN/AN/AN/AN/AC$198.42MC$83.74M58.86150CRDLCardiol TherapeuticsN/AC$2.53-0.8%N/A+125.0%C$176.80MN/A-5.7520News CoverageRXBioSyentN/AC$11.25-1.7%N/A+45.6%C$130.39MC$33.82M18.75N/ANews CoverageGap DownHLSHLS Therapeutics1.1399 of 5 starsC$3.40-2.0%C$3.63+6.6%-34.1%C$108.09MC$58.89M-3.3791Upcoming EarningsNews CoverageHigh Trading VolumeTGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940Gap UpWMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap Up Related Companies and Tools Related Companies ESSA Pharma Competitors ICC Labs Competitors RIV Capital Competitors Leaf Mobile Competitors Cardiol Therapeutics Competitors BioSyent Competitors HLS Therapeutics Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors WeedMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:MDP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
